Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition.

Wiltshire C, Singh BL, Stockley J, Fleming J, Doyle B, Barnetson R, Robson CN, Kozielski F, Leung HY.

Mol Cancer Ther. 2010 Jun;9(6):1730-9. doi: 10.1158/1535-7163.MCT-09-1103. Epub 2010 Jun 1.

2.

A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor.

Xing ND, Ding ST, Saito R, Nishizawa K, Kobayashi T, Inoue T, Oishi S, Fujii N, Lv JJ, Ogawa O, Nishiyama H.

Asian J Androl. 2011 Mar;13(2):236-41. doi: 10.1038/aja.2010.171. Epub 2011 Feb 7.

3.

Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5.

Debonis S, Skoufias DA, Indorato RL, Liger F, Marquet B, Laggner C, Joseph B, Kozielski F.

J Med Chem. 2008 Mar 13;51(5):1115-25. doi: 10.1021/jm070606z. Epub 2008 Feb 12.

PMID:
18266314
4.

STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity.

Indorato RL, DeBonis S, Kozielski F, Garcia-Saez I, Skoufias DA.

Biochem Pharmacol. 2013 Nov 15;86(10):1441-51. doi: 10.1016/j.bcp.2013.09.003. Epub 2013 Sep 13.

PMID:
24041742
5.

Proteome analysis of apoptosis signaling by S-trityl-L-cysteine, a potent reversible inhibitor of human mitotic kinesin Eg5.

Kozielski F, Skoufias DA, Indorato RL, Saoudi Y, Jungblut PR, Hustoft HK, Strozynski M, Thiede B.

Proteomics. 2008 Jan;8(2):289-300. doi: 10.1002/pmic.200700534.

PMID:
18186019
6.

In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities.

DeBonis S, Skoufias DA, Lebeau L, Lopez R, Robin G, Margolis RL, Wade RH, Kozielski F.

Mol Cancer Ther. 2004 Sep;3(9):1079-90.

7.

Eg5 inhibitor, a novel potent targeted therapy, induces cell apoptosis in renal cell carcinoma.

Ding S, Zhao Z, Sun D, Wu F, Bi D, Lu J, Xing N, Sun L, Wu H, Ding K.

Tumour Biol. 2014 Aug;35(8):7659-68. doi: 10.1007/s13277-014-2022-x. Epub 2014 May 7.

PMID:
24801905
8.

Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines.

Tcherniuk S, van Lis R, Kozielski F, Skoufias DA.

Biochem Pharmacol. 2010 Mar 15;79(6):864-72. doi: 10.1016/j.bcp.2009.11.001. Epub 2009 Nov 6.

PMID:
19896928
9.

Doing the methylene shuffle--further insights into the inhibition of mitotic kinesin Eg5 with S-trityl L-cysteine.

Abualhasan MN, Good JA, Wittayanarakul K, Anthony NG, Berretta G, Rath O, Kozielski F, Sutcliffe OB, Mackay SP.

Eur J Med Chem. 2012 Aug;54:483-98. doi: 10.1016/j.ejmech.2012.05.034. Epub 2012 Jun 7.

PMID:
22749640
10.

S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression.

Skoufias DA, DeBonis S, Saoudi Y, Lebeau L, Crevel I, Cross R, Wade RH, Hackney D, Kozielski F.

J Biol Chem. 2006 Jun 30;281(26):17559-69. Epub 2006 Feb 28.

11.

Synthesis and biological evaluation of L-cysteine derivatives as mitotic kinesin Eg5 inhibitors.

Ogo N, Oishi S, Matsuno K, Sawada J, Fujii N, Asai A.

Bioorg Med Chem Lett. 2007 Jul 15;17(14):3921-4. Epub 2007 May 3.

PMID:
17524640
12.

Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5.

Kaan HY, Weiss J, Menger D, Ulaganathan V, Tkocz K, Laggner C, Popowycz F, Joseph B, Kozielski F.

J Med Chem. 2011 Mar 24;54(6):1576-86. doi: 10.1021/jm100991m. Epub 2011 Feb 23.

PMID:
21344920
13.

Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5.

Brier S, Lemaire D, Debonis S, Forest E, Kozielski F.

Biochemistry. 2004 Oct 19;43(41):13072-82.

PMID:
15476401
14.

A potent chemotherapeutic strategy for bladder cancer: (S)-methoxy-trityl-L-cystein, a novel Eg5 inhibitor.

Ding S, Nishizawa K, Kobayashi T, Oishi S, Lv J, Fujii N, Ogawa O, Nishiyama H.

J Urol. 2010 Sep;184(3):1175-81. doi: 10.1016/j.juro.2010.04.073. Epub 2010 Jul 21.

PMID:
20663523
15.

Photocontrol of the mitotic kinesin Eg5 using a novel S-trityl-L-cysteine analogue as a photochromic inhibitor.

Ishikawa K, Tohyama K, Mitsuhashi S, Maruta S.

J Biochem. 2014 Apr;155(4):257-63. doi: 10.1093/jb/mvu004. Epub 2014 Jan 21.

PMID:
24451491
16.

Kif11 dependent cell cycle progression in radial glial cells is required for proper neurogenesis in the zebrafish neural tube.

Johnson K, Moriarty C, Tania N, Ortman A, DiPietrantonio K, Edens B, Eisenman J, Ok D, Krikorian S, Barragan J, Golé C, Barresi MJ.

Dev Biol. 2014 Mar 1;387(1):73-92. doi: 10.1016/j.ydbio.2013.12.021. Epub 2013 Dec 24.

17.

Terpendole E and its derivative inhibit STLC- and GSK-1-resistant Eg5.

Tarui Y, Chinen T, Nagumo Y, Motoyama T, Hayashi T, Hirota H, Muroi M, Ishii Y, Kondo H, Osada H, Usui T.

Chembiochem. 2014 May 5;15(7):934-8. doi: 10.1002/cbic.201300808. Epub 2014 Mar 19.

PMID:
24648249
18.
19.

Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer.

Howard EW, Lee DT, Chiu YT, Chua CW, Wang X, Wong YC.

Int J Cancer. 2008 May 1;122(9):1941-8. doi: 10.1002/ijc.23355.

20.

Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity.

Hayashi N, Koller E, Fazli L, Gleave ME.

Prostate. 2008 Sep 1;68(12):1283-95. doi: 10.1002/pros.20783.

PMID:
18512732

Supplemental Content

Support Center